-
TPPU: A Soluble Epoxide Hydrolase Inhibitor
2026-08-15
TPPU is a potent soluble epoxide hydrolase inhibitor with nanomolar activity against human and mouse sEH. Product and preclinical evidence supports its use for studying fatty acid epoxide signaling, inflammatory pain, and sEH-linked redox mechanisms, but it remains a research-use compound rather than a clinical treatment.
-
Ionomycin Calcium Salt: Calcium Signaling Guide
2026-08-14
Ionomycin calcium salt is a calcium ionophore that raises intracellular Ca2+ through release of stored calcium and extracellular influx. Research summaries link this activity to secretion, protein regulation, and apoptosis-related findings in HT1376 bladder cancer cells, while separate evidence defines the STIM1-Ca2+ pathway in prostate cancer metastasis.
-
Recombinant Annexin V on Endothelial Cells
2026-08-14
The 1994 reference study established that recombinant Annexin V binds cultured human endothelial cells with high affinity and suppresses cell-surface coagulation reactions. Its key contribution was to connect quantitative phosphatidylserine binding with inhibition of factor Xa and thrombin formation across several coagulation complexes, while showing that inflammatory or phorbol ester stimulation did not substantially alter Annexin V binding capacity.
-
10058-F4 c-Myc-Max Dimerization Inhibitor
2026-08-13
10058-F4 is a c-Myc-Max dimerization inhibitor used to investigate c-Myc transcription factor inhibition, apoptosis, acute myeloid leukemia, and prostate cancer models. Its reported activity is mechanistically relevant to recent evidence linking c-Myc:MAX activity with TERT transcription in human pluripotent stem cells.
-
ML-7 Hydrochloride: MLCK Inhibitor Guide
2026-08-13
ML-7 hydrochloride is a selective myosin light chain kinase inhibitor used to study MLC phosphorylation, cardiac contractility, and endothelial barrier signaling. Product information reports a Ki of 300 nM and research applications spanning ischemia/reperfusion injury research and vascular endothelial dysfunction models.
-
Quercetin, Hippo Signaling, and Cataract Protection
2026-08-12
A 2025 study identifies Hippo signaling as a mechanistic link between quercetin treatment, oxidative-stress control, and protection of lens epithelial cells in cataract models. Its combined network-pharmacology, animal, and cell-based design supports a role for Hippo-pathway modulation, while also leaving important questions about pathway specificity and translation unresolved.
-
Ginsenoside Rg1 in Neuroimmune Research
2026-08-12
Ginsenoside Rg1 enables a multimodal workflow linking behavior, synaptic physiology, inflammation, intestinal permeability, and regulatory T cells. This practical guide shows how to convert a prolonged-isoflurane mouse model into a controlled platform for neuroprotection research and mechanism testing.
-
Indomethacin as a Mechanistic Probe in Renal Inflammation
2026-08-11
Indomethacin is a nonsteroidal anti-inflammatory drug whose COX, PPAR, and membrane effects can reshape mechanistic inflammation research. This article presents a decision framework for using it alongside the FXR–KLF11 findings reported in contrast-induced kidney injury, with emphasis on assay interpretation and experimental controls.
-
CA800-PR Targets PGR Through Golgi Disruption
2026-08-11
The reference study introduces CA800-PR, a tumor-targeted heptamethine cyanine dye that combines near-infrared imaging with direct antitumor activity in hormone receptor-positive breast cancer models. Its reported mechanism links Golgi fragmentation, selective progesterone receptor suppression, apoptosis, and pro-inflammatory macrophage recruitment, offering a preclinical alternative to conventional endocrine therapy strategies.
-
SM-102 for mRNA Delivery: Evidence and Workflow
2026-08-10
SM-102 is a synthetic ionizable lipid used in lipid nanoparticle mRNA delivery systems. Product specifications define its chemical identity, solvent handling, storage, and purity, while peer-reviewed evidence shows that LNP performance depends on formulation composition and experimental conditions.
-
EZ Cap EGFP mRNA 5-moUTP: Assay Design Guide
2026-08-09
EZ Cap EGFP mRNA 5-moUTP combines Cap1, 5-moUTP, and an optimized poly(A) tail for consistent enhanced green fluorescent protein expression. This guide explains how to use the reporter to distinguish RNA delivery, intracellular release, translation, and innate immune effects.
-
GDC-0068: Mapping AKT–mTORC1 Signaling
2026-08-08
GDC-0068 (RG7440) is a selective pan-AKT inhibitor for dissecting PI3K/Akt/mTOR signaling. This article connects its pharmacology with new evidence on spatial mTORC1 control to improve mechanistic assay interpretation.
-
SM-102: From Vaccine Delivery to Localized mRNA Therapy
2026-08-07
SM-102 is more than a component of an mRNA vaccine delivery system: it is a formulation variable that can shape cellular uptake, endosomal escape, and translational performance. This thought-leadership analysis connects the mechanistic logic of SM-102 with emerging evidence for localized mRNA therapy, including intravesical p21 mRNA delivery in bladder cancer, while distinguishing validated findings from hypotheses that still require direct testing.
-
METTL17 Regulates Ferroptosis via Mitochondrial Translation
2026-08-07
A recent study reveals that the mitochondrial methyltransferase METTL17 protects colorectal cancer (CRC) cells from ferroptosis by regulating mitochondrial RNA methylation and translation. Targeting METTL17 enhances ferroptosis sensitivity and suppresses tumor progression, highlighting a new therapeutic axis in CRC.
-
Microfluidic Size Control of Lipid Nanoparticles for mRNA De
2026-08-06
Kim et al. present a simulation-driven approach to precisely control lipid nanoparticle (LNP) size via microfluidic chip design, revealing that smaller LNPs enhance mRNA delivery efficiency in vitro and in vivo. This work highlights nanoparticle size as an independent determinant of gene delivery outcomes, offering actionable guidance for future therapeutic and experimental applications.